Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | HTR1B | P28222 | 2/20 | 0.52 |
| ▸ | DRD4 | P21917 | 2/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.47 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.47 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96854 | 0.89 | KCNA3 (0.62) | KCNA3TAAR1ALDH1A1RECQLHTR1B | |
| SCHEMBL7363052 | 0.88 | KCNA3 (0.50) | KCNA3TAAR1ALDH1A1RECQLHTR1B | |
| SCHEMBL96602 | 0.87 | KCNA3 (0.67) | KCNA3TAAR1ALDH1A1RECQLHTR1B | |
| SCHEMBL5593684 | 0.85 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHTR1B | |
| SCHEMBL1172269 | 0.85 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHTR1B | |
| SCHEMBL96055 | 0.85 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHTR1B | |
| SCHEMBL7500091 | 0.85 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHTR1B | |
| SCHEMBL9683773 | 0.85 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHTR1B | |
| SCHEMBL2786288 | 0.85 | KCNA3 (0.64) | KCNA3TAAR1ALDH1A1RECQLHTR1B | |
| SCHEMBL16672084 | 0.84 | MAPK1 (0.42) | KCNA3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1465 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118222236-A | Dispersion adhesives | 科思创知识产权两合公司 | 2024-06-21 | — | — | CN | claimed |
| CN-117510338-A | Natural naphthoquinone derivative and preparation method and application thereof | 贵州大学 | 2024-02-06 | — | — | CN | claimed |
| CN-116783228-A | Storage-stable 1K spray adhesives based on polyurethane dispersions | 科思创德国股份有限公司 | 2023-09-19 | — | — | CN | claimed |
| CN-112867745-B | Dispersion adhesives | 科思创知识产权两合公司 | 2022-11-15 | — | — | CN | claimed |
| CN-114933620-A | Azithromycin derivatives having epithelial barrier enhancing properties | 艾比恩多制药有限责任公司 | 2022-08-23 | — | — | CN | claimed |
| US-20220106349-A1 | Compounds | EPIENDO PHARMACEUTICALS EHF (IS) | 2022-04-07 | — | — | US | claimed |
| US-11236120-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | EPIENDO PHARMACEUTICALS EHF (IS) | 2022-02-01 | — | — | US | claimed |
| CN-112867745-A | Dispersion adhesives | 科思创知识产权两合公司 | 2021-05-28 | — | — | CN | claimed |
| US-20200317710-A1 | Azithromycin Derivatives With Epithelial Barrier Enhancement Properties | EPIENDO PHARMACEUTICALS EHF (IS) | 2020-10-08 | — | — | US | claimed |
| EP-3708573-A1 | AZITHROMYCIN DERIVATIVES WITH EPITHELIAL BARRIER ENHANCEMENT PROPERTIES | EpiEndo Pharmaceuticals ehf. (IS) | 2020-09-16 | — | — | EP | claimed |
| US-4900863-A | Process for the purification of N-acylaspartame | HOECHST AKTIENGESELLSCHAFT (DE) | 1990-02-13 | — | — | US | claimed |
| WO-1989009611-A1 | CYCLIC ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-10-19 | — | — | WO | claimed |
| EP-0323740-A2 | Linear analogs of atrial natriuretic peptides | CALIFORNIA BIOTECHNOLOGY, INC. (US) | 1989-07-12 | — | — | EP | claimed |
| WO-1989005654-A1 | LINEAR ANALOGS OF ATRIAL NATRIURETIC PEPTIDES | CALIFORNIA BIOTECHNOLOGY INC. (US) | 1989-06-29 | — | — | WO | claimed |
| US-4438136-A | INHIBITION OF THROMBOXANE ACTIVITY | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1984-03-20 | — | — | US | claimed |
| EP-0013608-B1 | SUBSTITUTED BICYCLO (2,2,1)HEPTANES AND HEPT-2-ENES AND THEIR PHARMACEUTICAL COMPOSITIONS | NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) | 1983-06-15 | — | — | EP | claimed |
| US-4269773-A | CEPHALOSPORINS | SHIONOGI & CO., LTD. (JP) | 1981-05-26 | — | — | US | claimed |
| EP-0003584-B1 | PHENOXYPROPANOIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS HERBICIDES | BAYER AG (DE) | 1981-01-21 | — | — | EP | claimed |
| US-4070458-A | MICRBIAL ENZYME | SANRAKU-OCEAN CO., LTD. (JA) | 1978-01-24 | — | — | US | claimed |
| US-4055468-A | TETRAPEPTIDE | SANRAKU-OCEAN CO., LTD. (JA) | 1977-10-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106349-A1 | Compounds | CFTR, AQP1, CTSA | KCNA3 1966/4885TAAR1 4878/4885ALDH1A1 1837/4885 |
| US-11236120-B2 | Azithromycin derivatives with epithelial barrier enhancement properties | CFTR, AQP1, CTSA | KCNA3 1973/4885TAAR1 4867/4885ALDH1A1 2483/4885 |
| US-20200317710-A1 | Azithromycin Derivatives With Epithelial Barrier Enhancement Properties | CFTR, AQP1, CTSA | KCNA3 1973/4885TAAR1 4867/4885ALDH1A1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.